AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Baxdrostat is an investigational highly selective, oral, small molecule designed to inhibit aldosterone synthase.

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

AstraZeneca Plc’s experimental hypertension drug Baxdrostat reduced the blood pressure of patients who have an uncontrolled ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

As President Donald Trump’s tariff policies loom, global pharmaceutical giant AstraZeneca will invest $50 billion to boost ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a ...

AstraZeneca said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S.

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...